top of page
new hero solo woman-Recovered2.jpg

At the Forefront of the New Science of Cell-free RNA

Resolving Inflammation Without Immunosuppression

rnr final web.jpg

A Fresh Approach

Our core belief is that the medicines of tomorrow will eliminate the cause of inflammation rather than shut down key elements of the immune system.

Our Science

Our fully-human biologic drug platform combines RNases and DNases with an antibody Fc to remove extracellular nucleic acids including RNA, DNA and neutrophil extracellular traps (NETs), which restores homeostasis and resolves inflammation. We are applying this technology across multiple acute and chronic diseases with high unmet need. 

resolve molecule final.jpg
flowsaber_A_beautiful_cinematic_shot_of_a_65_year_old_native_am_58f7513b-2458-4c7c-96ad-2e

Our Clinical Trial

Resolve is currently evaluating RSLV-132 in a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Sjögren’s Syndrome.

News and Events

May 28, 2025

Resolve Therapeutics and Duke Medical School Initiate Observational Study of Cell-free RNA in Polytrauma Patients.

May 13, 2024

Resolve Therapeutics Publishes Results of RSLV-132 Phase 2 Long COVID Study

May 13, 2024

Resolve Therapeutics Announces Publication of Lupus Clinical Trial Results

ResolveBioLogo-final-09.png
bottom of page